The significant cost of systematic reviews and meta-analyses: A call for greater involvement of machine learning to assess the promise of clinical trials

Abstract

With the increase in the number of publications, the significant time and cost of SLR may pose a barrier to their consistent application to assess the promise of clinical trials thoroughly. We call on investigators and developers to develop automated solutions to help with the assessment of preclinical evidence particularly. The formula we introduce provides a cost baseline against which the efficiency of automation can be measured.